ESR1 and breast cancer: In the PADA-1 trial, for instance, switching endocrine treatment to fulvestrant (with palbociclib) in patients with luminal BC with emergent ESR1 mutation detected by ctDNA (in the absence of radiological progression), increased progression-free survival (PFS) compared to maintaining the letrozole treatment backbone10.